drugset / Trial / NCT05285540
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Timeline
- Start
- 2022-03-11
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DT-216 | Unknown | — | Intravenous |